First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors.
H. Hayashi
No relevant relationships to disclose
T. Kurata
No relevant relationships to disclose
Y. Fujisaka
No relevant relationships to disclose
T. Satoh
No relevant relationships to disclose
M. Takeda
No relevant relationships to disclose
M. Miyazaki
No relevant relationships to disclose
T. Okabe
No relevant relationships to disclose
H. Kiyota
No relevant relationships to disclose
K. Tanaka
No relevant relationships to disclose
T. Tsunoda
Employment or Leadership Position - OncoTherapy Science
K. Nakagawa
No relevant relationships to disclose